CategoryArchive

COVID Ofatumumab

Adamec I, Rogić D, Penz MG, Braun C, Habek M. Humoral and cellular immunity in convalescent COVID-19 people with multiple sclerosis treated with ofatumumab. J Neuroimmunol. 2021 3;362:577788. doi: 10.1016/j.jneuroim.2021.577788. Objectives: To report clinical outcome, development of humoral and T-cell mediated immunity in convalescent COVID-19 people with multiple sclerosis (pwMS) treated...

COVID in children

Young people who get COVID-19 do OK.this is not suprising because they have a young set of macrophages and few of the comobidities that contribute to the risk Olivé-Cirera et al. Impact of COVID-19 in Immunosuppressed Children With Neuroimmunologic Disorders. Neurology Neuroinflammation, Neuroimmunology 2021, DOI: Background and Objectives To investigate whether children receiving...

Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing

This is a debate close to my brain and the pros and cons have been debated in an MS journal. You know I’m biased and believe that studies should be done by the makers of anti-CD20 depleting antibodies, but what do other people (in blue saying no) think and say. “Anti-CD20 MS drugs are highly effective in treating relapsing MS in their current approved treatment regimens (ocrelizumab...

Covid-MS

Someone asked about the course of COVID-19 and why you are OK and then not and so and I wish them a speedy recovery. When you get infected it takes a few days for symptom onset, generally about 5 days and with omicron it may be a few days quicker. When symptoms appear your clock is ticking. You have five days to be offered anti-virals if you fit the bill in terms of risk. So make sure you can...

EBV vaccine studies begins Good Luck and Good Hunting

A New Years present for some. Some people have been suggesting that EBV is the cause of MS. It may well be but how do you you prove it? Get rid of EBV and hope that MS goes away…..we may say. Some people believe it is the target for the immune response in MS, but many people do not think this is the case and can make up many alternative ideas of how EBV could be important. If it is the...

The crystal balls for 2022 and beyond..Entering inpenetrable into the brain

During the new year I guess we have to look to the future and to look in the pharma crystal ball to see what is coming your way in the near future. I have had a look at pharma’s balls. These are called product piplelines and I have had a glance at those from the companies that make MS drugs and can see that many are testing Brutons Tyrsosine kinase inhibitors to target the B cells and also...

Will 2022 be the year AI-assisted MRI enters the management of pwMS?

Regular MRI is a key element in the follow-up of pwMS, particularly those on disease modifying treatment (DMT). Why? Because MRI is significantly more sensitive in detecting MS disease activity than counting relapses and measuring disability using the EDSS (Kurtzke’s Expanded Disability Status Scale). I’m quite precise here referring to the EDSS since other clinical instruments may be...

Q&A 2022 Jan 1.1.

If you have a question, this is the place for you. I hope you have enjoyed the beautiful work of ANDRZEJ SZYMCZYK Andrzej is a local artist with a studio in Bow Syphinx cat Syphinxman Andrejz has a piece in Leicester Square (Home of the London Cinemas) Harry Potter in Leicester square. Disclaimer: Please note that the opinions expressed here are those of the author and do not reflect the...

Another anti-viral approved in UK

Paxlovid is the second new antiviral pill to be approved for Covid in the UK after molnupiravir was approved in November. Again you need to get on drug within about 5 days after symptom onset Apparently according to the media Paxlovid will be made available through 70 new hospital clinics known as NHS Covid medicine delivery units, and sent directly to the door of eligible patients infected. Some...

Translate

Categories

Recent Posts

Recent Comments

Archives